Theratechnologies Inc. (NASDAQ:THTX) Short Interest Up 26.8% in October

Theratechnologies Inc. (NASDAQ:THTX) saw a large increase in short interest in October. As of October 31st, there was short interest totalling 43,000 shares, an increase of 26.8% from the October 15th total of 33,900 shares. Based on an average trading volume of 33,400 shares, the days-to-cover ratio is presently 1.3 days. Approximately 0.2% of the shares of the stock are short sold.

Institutional Trading of Theratechnologies

An institutional investor recently raised its position in Theratechnologies stock. Cyndeo Wealth Partners LLC raised its holdings in shares of Theratechnologies Inc. (NASDAQ:THTX) by 26.1% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 131,311 shares of the company’s stock after buying an additional 27,191 shares during the quarter. Cyndeo Wealth Partners LLC owned about 0.29% of Theratechnologies worth $163,000 as of its most recent SEC filing.

Theratechnologies Trading Down 2.5 %

THTX traded down $0.03 during midday trading on Friday, hitting $1.18. 15,002 shares of the company traded hands, compared to its average volume of 44,228. The business has a 50 day simple moving average of $1.25 and a two-hundred day simple moving average of $1.31. Theratechnologies has a 52-week low of $1.08 and a 52-week high of $2.58. The company has a market capitalization of $54.26 million, a price-to-earnings ratio of -11.80 and a beta of 1.41.

Theratechnologies (NASDAQ:THTX) last issued its quarterly earnings results on Thursday, October 10th. The company reported $0.06 earnings per share for the quarter, beating analysts’ consensus estimates of $0.03 by $0.03. The company had revenue of $22.60 million during the quarter. During the same quarter in the previous year, the company earned ($0.03) earnings per share. Equities research analysts anticipate that Theratechnologies will post 0.03 earnings per share for the current year.

About Theratechnologies

Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.